Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Similar articles for PubMed (Select 24333316)

1.

The demand for factor VIII and for factor IX and the toll fractionation product surplus management.

Calizzani G, Profili S, Candura F, Lanzoni M, Vaglio S, Cannata L, Liumbruno GM, Franchini M, Mannucci PM, Grazzini G.

Blood Transfus. 2013 Sep;11 Suppl 4:s64-76. doi: 10.2450/2013.011s. Review. No abstract available.

2.

Clinical use of factor VIII and factor IX concentrates.

Morfini M, Coppola A, Franchini M, Di Minno G.

Blood Transfus. 2013 Sep;11 Suppl 4:s55-63. doi: 10.2450/2013.010s. Review. No abstract available.

3.

Letter: Blood fractions for haemophilia.

Aledort LM.

Lancet. 1974 Dec 14;2(7894):1452. No abstract available.

PMID:
4140363
4.

Will recent innovations in therapy save perceived deficiencies in self-sufficiency policies.

Limentani SA.

Blood Coagul Fibrinolysis. 1994 Dec;5 Suppl 4:S81-4.

PMID:
7795145
5.

Production of antihemophilic factor in France.

Allain JP.

Scand J Haematol Suppl. 1984;40:499-503. No abstract available.

PMID:
6433471
6.

Prophylaxis for adults with haemophilia: one size does not fit all.

Fischer K.

Blood Transfus. 2012 Apr;10(2):169-73. doi: 10.2450/2012.0174-11. No abstract available.

7.

Prophylaxis in haemophilia should be life-long.

Makris M.

Blood Transfus. 2012 Apr;10(2):165-8. doi: 10.2450/2012.0147-11. Epub 2012 Feb 13. No abstract available.

8.

Factor products in the treatment of hemophilia.

Miller KL.

J Pediatr Health Care. 2004 May-Jun;18(3):156-7. No abstract available.

PMID:
15129219
9.

[Blood derivatives in the treatment of hemophilia in Spain. Present and future needs].

Medarde A, Ayesa C, Alfonso L, Muñóz A.

Sangre (Barc). 1979;24(5-C):942-6. Spanish. No abstract available.

PMID:
121170
10.

Maintenance of treatment logs by haemophilia patients.

du Treil S, Rice J, Leissinger CA.

Haemophilia. 2010 May;16(3):545-7. doi: 10.1111/j.1365-2516.2009.02169.x. Epub 2009 Dec 29. No abstract available.

PMID:
20050930
11.

[Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].

Iizuka A, Kuwashima M, Nagao T.

Nihon Ketsueki Gakkai Zasshi. 1982 Sep;45(5):987-92. Japanese. No abstract available.

PMID:
6818811
12.

Management of joint bleeding in hemophilia.

Simpson ML, Valentino LA.

Expert Rev Hematol. 2012 Aug;5(4):459-68. Review.

PMID:
22992238
13.

Chronic arthropathy management in haemophilia: assessing the impact of a new model of care.

d'Young I, Young L, Brasser M, Ockelford P.

N Z Med J. 2012 Apr 20;125(1353):161-3. No abstract available.

PMID:
22522280
14.

Fractionation of factor VIII and IX--an overview.

Johnson AJ, Mathews RW, Fulton AJ.

Scand J Haematol Suppl. 1984;40:513-24. No abstract available.

PMID:
6433474
15.
16.

Concentrated therapeutic fractions of coagulation factors prepared in Europe.

Soulier JP.

Thromb Diath Haemorrh Suppl. 1967;26:391-400. No abstract available.

PMID:
6064869
17.

Cataract surgery in haemophilia.

Mauser-Bunschoten EP, Bijlsma W, Roosendaal G, Schutgens RE.

Haemophilia. 2013 Nov;19(6):e371-2. doi: 10.1111/hae.12212. Epub 2013 Jun 17. No abstract available.

PMID:
23773276
18.

Identifying and overcoming barriers to prophylaxis in the management of haemophilia.

Petrini P.

Haemophilia. 2007 Sep;13 Suppl 2:16-22. Review.

PMID:
17685919
19.

Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor.

Fukui H, Fujimura Y, Takahashi Y, Mikami S, Yoshioka A.

Thromb Res. 1981 Apr 1-15;22(1-2):177-84. No abstract available.

PMID:
6794176
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk